| References |
1. Kashiwagi H, Yuhki K, Kojima F, Kumei S, Takahata O, Sakai Y, Narumiya S, Ushikubi F. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015 May;353(2):269-78. doi: 10.1124/jpet.115.222612. Epub 2015 Mar 4. PubMed PMID: 25740898. 2. Watatani H, Yamasaki H, Maeshima Y, Nasu T, Hinamoto N, Ujike H, Sugiyama H, Sakai Y, Tanabe K, Makino H. ONO-1301, a sustained-release prostacyclin analog, ameliorates the renal alterations in a mouse type 2 diabetes model possibly through its protective effects on mesangial cells. Acta Med Okayama. 2015;69(1):1-15. PubMed PMID: 25703166. 3. Hazekawa M, Morihata K, Yoshida M, Sakai Y, Uchida T. The angiogenic effect of ONO-1301, a novel long-acting prostacyclin agonist loaded in PLGA microspheres prepared using different molecular weights of PLGA, in a murine sponge model. Drug Dev Ind Pharm. 2014 Nov;40(11):1435-42. doi: 10.3109/03639045.2013.828220. Epub 2013 Aug 13. PubMed PMID: 23937583. 4. Niina Y, Ito T, Oono T, Nakamura T, Fujimori N, Igarashi H, Sakai Y, Takayanagi R. A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology. 2014 May-Jun;14(3):201-10. doi: 10.1016/j.pan.2014.02.009. Epub 2014 Mar 15. PubMed PMID: 24854616. |
